CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma

@article{Sibin2015CDKN2AM,
  title={CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma},
  author={M. K. Sibin and Dhananjaya Ishwar Bhat and Kanchana Narasingarao and Ch. Lavanya and G K Chetan},
  journal={Tumor Biology},
  year={2015},
  volume={36},
  pages={7607-7614}
}
Human high-grade glioma is heterogeneous in nature based on pathological and genetic profiling. Various tumour suppressor gene alterations are considered as prognostic markers in high-grade glioma. Gene expression of CDKN2A (p16) is used in various cancers as a prognostic biomarker along with methylation and deletion status of this gene. Expression levels of p16 mRNA were not studied as a biomarker in gliomas before. In this study, we have performed mRNA quantification analysis on 48 high-grade… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Overexpression and lack of copy number variation in BMI-1 gene in human glioma from Indian population

  • MK Sibin, DI Bhat, C Lavanya, S Arati, GK. Chetan
  • Oncology Letters. ;(In Press)
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…